O	0	7	Topical
O	8	11	use
O	12	14	of
B-intervention	15	26	recombinant
I-intervention	27	32	human
I-intervention	33	42	epidermal
I-intervention	43	49	growth
I-intervention	50	56	factor
I-intervention	57	58	(
I-intervention	58	61	EGF
I-intervention	61	62	)
I-intervention	62	63	-
I-intervention	63	68	based
I-intervention	69	74	cream
O	75	77	to
O	78	85	prevent
B-condition	86	95	radiation
I-condition	96	106	dermatitis
O	107	109	in
O	110	116	breast
O	117	123	cancer
O	124	132	patients
O	132	133	:
O	134	135	a
O	136	142	single
O	142	143	-
O	143	148	blind
O	149	159	randomized
O	160	171	preliminary
O	172	177	study
O	177	178	.

O	179	182	The
O	183	190	purpose
O	191	193	of
O	194	198	this
O	199	204	study
O	205	208	was
O	209	211	to
O	212	218	assess
O	219	222	the
O	223	236	effectiveness
O	237	239	of
O	240	241	a
O	242	253	recombinant
O	254	259	human
O	260	269	epidermal
O	270	276	growth
O	277	283	factor
O	284	285	(
O	285	288	EGF
O	288	289	)
O	289	290	-
O	290	295	based
O	296	301	cream
O	302	305	for
O	306	309	the
O	310	320	prevention
O	321	323	of
O	324	329	acute
O	330	339	radiation
O	340	350	dermatitis
O	351	353	in
O	354	360	breast
O	361	367	cancer
O	368	376	patients
O	377	386	receiving
O	387	399	radiotherapy
O	400	401	(
O	401	403	RT
O	403	404	)
O	404	405	.

O	406	413	Between
O	414	422	December
O	423	427	2012
O	428	431	and
O	432	437	April
O	438	442	2013
O	442	443	,
B-total-participants	444	446	40
B-eligibility	447	453	breast
I-eligibility	454	460	cancer
I-eligibility	461	469	patients
I-eligibility	470	473	who
I-eligibility	474	482	received
I-eligibility	483	496	postoperative
I-eligibility	497	499	RT
I-eligibility	500	504	were
I-eligibility	505	518	prospectively
O	519	527	enrolled
O	528	530	in
O	531	535	this
O	536	541	study
O	542	545	and
O	546	554	randomly
O	555	563	assigned
O	564	566	to
O	567	574	receive
O	575	580	human
O	581	592	recombinant
O	593	596	EGF
O	596	597	-
O	597	602	based
O	603	608	cream
O	609	610	(
O	610	622	intervention
O	623	628	group
O	628	629	)
O	630	632	or
B-control	633	640	general
I-control	641	651	supportive
I-control	652	656	skin
I-control	657	661	care
I-control	662	663	(
I-control	663	670	control
I-control	671	676	group
I-control	676	677	)
O	677	678	.

O	679	682	The
O	683	688	grade
O	689	691	of
O	692	701	radiation
O	702	712	dermatitis
O	713	716	and
O	717	721	pain
O	722	727	score
O	728	732	were
O	733	741	examined
O	742	744	at
O	745	751	weekly
O	752	761	intervals
O	762	768	during
O	769	771	RT
O	772	775	and
O	776	777	6
O	778	783	weeks
O	784	789	after
O	790	792	RT
O	793	803	completion
O	803	804	.

O	805	808	All
O	809	817	patients
O	818	827	completed
O	828	831	the
O	832	839	planned
O	840	842	RT
O	843	846	and
O	847	855	complied
O	856	860	well
O	861	865	with
O	866	878	instructions
O	879	882	for
O	883	891	applying
O	892	895	the
O	896	901	study
O	902	907	cream
O	908	911	and
O	912	919	general
O	920	930	supportive
O	931	935	skin
O	936	940	care
O	940	941	.

O	942	944	In
O	945	948	the
O	949	961	intervention
O	962	967	group
O	967	968	,
B-outcome	969	978	radiation
I-outcome	979	989	dermatitis
I-outcome	990	992	of
I-outcome	993	1000	maximum
I-outcome	1001	1006	grade
I-outcome	1007	1008	3
I-outcome	1008	1009	,
I-outcome	1010	1011	2
I-outcome	1011	1012	,
I-outcome	1013	1016	and
I-outcome	1017	1018	1
O	1019	1028	developed
O	1029	1031	in
B-iv-bin-abs	1032	1033	3
O	1034	1035	(
B-iv-bin-percent	1035	1037	15
I-iv-bin-percent	1037	1038	%
O	1038	1039	)
O	1039	1040	,
B-iv-bin-abs	1041	1043	11
O	1044	1045	(
B-iv-bin-percent	1045	1047	55
I-iv-bin-percent	1047	1048	%
O	1048	1049	)
O	1049	1050	,
O	1051	1054	and
B-iv-bin-abs	1055	1056	6
O	1057	1065	patients
O	1066	1067	(
B-iv-bin-percent	1067	1069	30
I-iv-bin-percent	1069	1070	%
O	1070	1071	)
O	1071	1072	,
O	1073	1085	respectively
O	1085	1086	.

O	1087	1089	In
O	1090	1100	comparison
O	1100	1101	,
O	1102	1104	in
O	1105	1108	the
O	1109	1116	control
O	1117	1122	group
O	1122	1123	,
B-outcome	1124	1133	radiation
I-outcome	1134	1144	dermatitis
I-outcome	1145	1147	of
I-outcome	1148	1155	maximum
I-outcome	1156	1161	grade
I-outcome	1162	1163	3
I-outcome	1163	1164	,
I-outcome	1165	1166	2
I-outcome	1166	1167	,
I-outcome	1168	1171	and
I-outcome	1172	1173	1
O	1174	1183	developed
O	1184	1186	in
B-cv-bin-abs	1187	1188	8
O	1189	1190	(
B-cv-bin-percent	1190	1192	40
I-cv-bin-percent	1192	1193	%
O	1193	1194	)
O	1194	1195	,
B-cv-bin-abs	1196	1198	10
O	1199	1200	(
B-cv-bin-percent	1200	1202	50
I-cv-bin-percent	1202	1203	%
O	1203	1204	)
O	1204	1205	,
O	1206	1209	and
B-cv-bin-abs	1210	1211	2
O	1212	1220	patients
O	1221	1222	(
B-cv-bin-percent	1222	1224	10
I-cv-bin-percent	1224	1225	%
O	1225	1226	)
O	1226	1227	,
O	1228	1240	respectively
O	1240	1241	.

O	1242	1245	The
O	1246	1258	intervention
O	1259	1264	group
O	1265	1271	showed
O	1272	1277	lower
B-outcome	1278	1287	incidence
I-outcome	1288	1290	of
I-outcome	1291	1296	grade
I-outcome	1297	1298	3
I-outcome	1299	1308	radiation
I-outcome	1309	1319	dermatitis
O	1320	1324	than
O	1325	1328	the
O	1329	1336	control
O	1337	1342	group
O	1343	1344	(
O	1344	1345	p
O	1345	1346	=
O	1346	1347	0
O	1347	1348	.
O	1348	1351	068
O	1352	1354	in
O	1355	1365	univariate
O	1366	1374	analysis
O	1375	1378	and
O	1379	1380	p
O	1380	1381	=
O	1381	1382	0
O	1382	1383	.
O	1383	1386	035
O	1387	1389	in
O	1390	1402	multivariate
O	1403	1411	analysis
O	1411	1412	)
O	1412	1413	.

O	1414	1419	There
O	1420	1423	was
O	1424	1426	no
O	1427	1440	statistically
O	1441	1452	significant
O	1453	1463	difference
O	1464	1466	in
O	1467	1470	the
O	1471	1478	maximal
B-outcome	1479	1483	pain
I-outcome	1484	1489	score
O	1490	1497	between
O	1498	1501	the
O	1502	1505	two
O	1506	1512	groups
O	1513	1514	(
O	1514	1515	p
O	1515	1516	=
O	1516	1517	0
O	1517	1518	.
O	1518	1521	934
O	1521	1522	)
O	1522	1523	.

O	1524	1528	This
O	1529	1535	single
O	1535	1536	-
O	1536	1541	blind
O	1542	1552	randomized
O	1553	1564	preliminary
O	1565	1570	study
O	1571	1577	showed
O	1578	1582	that
O	1583	1594	recombinant
O	1595	1600	human
O	1601	1604	EGF
O	1604	1605	-
O	1605	1610	based
O	1611	1616	cream
O	1617	1620	can
O	1621	1625	have
O	1626	1627	a
O	1628	1638	beneficial
O	1639	1643	role
O	1644	1646	in
O	1647	1657	preventing
O	1658	1660	or
O	1661	1671	minimizing
O	1672	1681	radiation
O	1682	1692	dermatitis
O	1693	1695	in
O	1696	1702	breast
O	1703	1709	cancer
O	1710	1718	patients
O	1718	1719	.

O	1720	1722	To
O	1723	1730	confirm
O	1731	1734	the
O	1735	1742	results
O	1743	1745	of
O	1746	1749	our
O	1750	1755	study
O	1755	1756	,
O	1757	1767	additional
O	1768	1775	studies
O	1776	1780	with
O	1781	1782	a
O	1783	1788	large
O	1789	1795	sample
O	1796	1800	size
O	1801	1804	are
O	1805	1813	required
O	1813	1814	.
